U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07843862) titled 'A Study of HRS-4729 Injection in Participants With Type 2 Diabetes' on Sept. 22.

Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: HRS-4729 Injection

HRS-4729 Injection

DRUG: Mazdutide

Mazdutide

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Published by H...